HOME >> BIOLOGY >> NEWS
New genetic 'fishing net' harvests elusive autism gene

DURHAM, N.C. -- Duke University Medical Center researchers have developed a new statistical genetic "fishing net" that they have cast into a sea of complex genetic data on autistic children to harvest an elusive autism gene.

Moreover, the researchers said that the success of the approach will be broadly applicable to studying genetic risk factors for other complex genetic diseases, such as hypertension, diabetes and multiple sclerosis.

In this case, the gene, which encodes part of a brain neurotransmitter docking station called the gamma-Aminobutyric Acid Receptor beta3-subunit (GABRB3), has been implicated in autism previously, but never positively linked to the disease. Their findings will be published in the March 2003 issue of the American Journal of Human Genetics and is now available on the Web at http://www.journals.uchicago.edu/AJHG/journal/issues/v72n3/024607/024607.html.

"Many research groups have been actively looking for genetic risk factors that can lead to autism, but without much success," said Margaret Pericak-Vance, Ph.D., director of the Duke Center for Human Genetics and lead investigator of the study.

Autism is the common term that encompasses an overlapping group of complex developmental disorders that are diagnosed in about one in 1,000 children under the age of 3. Each autistic child has a unique set of characteristics that affect his or her behavior, communication skills and ability to interact with others. It is the very diverse, complex nature of autism that has made it so difficult to locate distinct genetic risk factors, said Pericak-Vance.

After several genetic studies turned up only a few vague genetic clues, the research team decided a new approach was needed. Pericak-Vance hypothesized that grouping patients with similar traits together statistically might enhance the scientist
'"/>

Contact: Richard Puff
richard.puff@duke.edu
919-684-4148
Duke University Medical Center
6-Feb-2003


Page: 1 2 3

Related biology news :

1. Researchers determine genetic cause of Timothy syndrome
2. Rare childhood genetic syndrome identified
3. New research shows plants can shuffle and paste gene pieces to generate genetic diversity
4. Scientists decipher genetic code of biothreat pathogen
5. Chemical genetics identifies SARS inhibitors
6. 22nd amino acid synthesized and added to genetic code of e. coli bacteria
7. The impact of genetic variations on the treatment of early rheumatoid arthritis
8. Adaptive changes in the genome may provide insight into the genetics of complex disease
9. New genetic hypothesis for the cause of autism
10. Fossils reveal direct link between global warming and genetic diversity in wildlife
11. A genetic disorder yields insight into genes and cognition

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New genetic fishing net harvests elusive autism gene

(Date:3/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4stcg3/india_sensors ... "India Sensors Market Forecast and Opportunities 2020" ... market is projected to grow at a CAGR ... automotive, industrial and healthcare sectors are the key ... addition, adoption of MEMS technology in sensors is ...
(Date:3/19/2015)... 19, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, announces its biometric payment technology, ... that aired this week on Washington DC,s ... In a segment "The Next Great Thing", host Laura ... to pay, and ,a really big breakthrough in mobile payment.,  ...
(Date:3/17/2015)... 2015  MecklerMedia Corporation (OTCQX: MECK) announced its ... robots ever held in New York ... 11-13, 2015 at the Javits Convention Center. ... include: Acorn Product Development; Axis NJ; c-Link Systems; ... Littler; NewBotic Corporation; Neya Systems LLC; Reliabotics; RoboKind; ...
Breaking Biology News(10 mins):India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2
(Date:3/30/2015)... PMG Research, Benchmark Research, and ... formation of VaxCorps, a network of highly experienced, ... conduct of vaccine trials in healthy adult, elderly, ... successfully conducted over 500 phase I-III vaccine clinical ... influenza as well as a vast array of ...
(Date:3/30/2015)... IRVINE, Calif. , March 30, 2015 /PRNewswire/ ... that its subsidiary corporation, NuGene BioPharma, Inc. has ... board. Dr. Guan is an internationally ... After finishing his college education at Peking University, ... his Ph.D. degree from the University of North ...
(Date:3/30/2015)... ROCKVILLE, Md. , March 30, 2015 ... company dedicated to the acquisition, development and commercialization of ... for the global market with a commercial focus on ... China Food and Drug Administration (CFDA) has approved the ... trial in ovarian clear cell carcinoma (OCCC) patients for ...
(Date:3/30/2015)... 30, 2015  Spherix Incorporated (Nasdaq: SPEX ... fostering and monetization of intellectual property, today provided ... 3:13-cv-03494-M and  Spherix v. Uniden , Case No. ... for the Northern District of Texas ... v. Verizon, Case No. 1:14-cv-00721-GBL-TCB, in the ...
Breaking Biology Technology:PMG Research announces formation of VaxCorps with two industry-leading vaccine site networks 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 2Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 3
Cached News: